WO2002101043A3 - Regulation du recepteur ta4 humain - Google Patents

Regulation du recepteur ta4 humain Download PDF

Info

Publication number
WO2002101043A3
WO2002101043A3 PCT/EP2002/006204 EP0206204W WO02101043A3 WO 2002101043 A3 WO2002101043 A3 WO 2002101043A3 EP 0206204 W EP0206204 W EP 0206204W WO 02101043 A3 WO02101043 A3 WO 02101043A3
Authority
WO
WIPO (PCT)
Prior art keywords
human
receptor
disorders
lio
reagents
Prior art date
Application number
PCT/EP2002/006204
Other languages
English (en)
Other versions
WO2002101043A2 (fr
Inventor
Zhimin Zhu
Original Assignee
Bayer Ag
Zhimin Zhu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag, Zhimin Zhu filed Critical Bayer Ag
Publication of WO2002101043A2 publication Critical patent/WO2002101043A2/fr
Publication of WO2002101043A3 publication Critical patent/WO2002101043A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Cette invention se rapporte à des réactifs qui régulent le récepteur TA4 humain et à des réactifs qui se fixent à des produits géniques du récepteur TA4 humain, jouant ainsi un rôle dans la prévention, la diminution ou la correction des dysfonctionnements ou des maladies telles que notamment les affections hématologiques, la broncho-pneumopathie chronique obstructive, l'asthme, les troubles cardio-vasculaires, les troubles du système nerveux central, le diabète, l'obésité, le cancer et les affections génito-urinaires.
PCT/EP2002/006204 2001-06-08 2002-06-06 Regulation du recepteur ta4 humain WO2002101043A2 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US29644701P 2001-06-08 2001-06-08
US60/296,447 2001-06-08
US33139301P 2001-11-15 2001-11-15
US60/331,393 2001-11-15
US37281102P 2002-04-17 2002-04-17
US60/372,811 2002-04-17

Publications (2)

Publication Number Publication Date
WO2002101043A2 WO2002101043A2 (fr) 2002-12-19
WO2002101043A3 true WO2002101043A3 (fr) 2003-08-28

Family

ID=27404433

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/006204 WO2002101043A2 (fr) 2001-06-08 2002-06-06 Regulation du recepteur ta4 humain

Country Status (1)

Country Link
WO (1) WO2002101043A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003244637A1 (en) * 2002-07-16 2004-02-02 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with homo sapiens putative neurotransmitter receptor (pnr)
EP1626057A1 (fr) * 2004-07-30 2006-02-15 F.Hoffmann-La Roche Ag Récepteurs du chimpanzé associés aux "trace amines"

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000060081A1 (fr) * 1999-04-06 2000-10-12 Synaptic Pharmaceutical Corporation Adn codant pour des recepteurs orphelins
WO2000073449A1 (fr) * 1999-05-28 2000-12-07 Synaptic Pharmaceutical Corporation Adn codant pour le recepteur snorf33
WO2001036473A2 (fr) * 1999-11-16 2001-05-25 Pharmacia & Upjohn Company Recepteurs couples a une proteine g
WO2002034913A2 (fr) * 2000-10-24 2002-05-02 Pe Corporation (Ny) Recepteurs couples aux proteines g humains, isoles, molecules d'acide nucleique codant ces proteines humaines des recepteurs couples aux proteines g (gpcr), et leurs applications
WO2002042461A2 (fr) * 2000-11-27 2002-05-30 Arena Pharmaceuticals, Inc. Versions endogene et non endogene de recepteurs couples aux proteines g humaines
WO2002061075A1 (fr) * 2001-02-01 2002-08-08 Takeda Chemical Industries, Ltd. Proteine de recepteur couple aux proteines g et adn correspondant

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000060081A1 (fr) * 1999-04-06 2000-10-12 Synaptic Pharmaceutical Corporation Adn codant pour des recepteurs orphelins
WO2000073449A1 (fr) * 1999-05-28 2000-12-07 Synaptic Pharmaceutical Corporation Adn codant pour le recepteur snorf33
WO2001036473A2 (fr) * 1999-11-16 2001-05-25 Pharmacia & Upjohn Company Recepteurs couples a une proteine g
WO2002034913A2 (fr) * 2000-10-24 2002-05-02 Pe Corporation (Ny) Recepteurs couples aux proteines g humains, isoles, molecules d'acide nucleique codant ces proteines humaines des recepteurs couples aux proteines g (gpcr), et leurs applications
WO2002042461A2 (fr) * 2000-11-27 2002-05-30 Arena Pharmaceuticals, Inc. Versions endogene et non endogene de recepteurs couples aux proteines g humaines
WO2002061075A1 (fr) * 2001-02-01 2002-08-08 Takeda Chemical Industries, Ltd. Proteine de recepteur couple aux proteines g et adn correspondant

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ATTWOOD T K: "A compendium of specific motifs for diagnosing GPCR subtypes", TRENDS IN PHARMACOLOGICAL SCIENCES, ELSEVIER TRENDS JOURNAL, CAMBRIDGE, GB, vol. 22, no. 4, 1 April 2001 (2001-04-01), pages 162 - 165, XP004231938, ISSN: 0165-6147 *
BOROWSKY B ET AL: "Trace amines: Identification of a family of mammalian G protein-coupled receptors", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 98, no. 16, 31 July 2001 (2001-07-31), pages 8966 - 8971, XP002185201, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
WO2002101043A2 (fr) 2002-12-19

Similar Documents

Publication Publication Date Title
WO2002101043A3 (fr) Regulation du recepteur ta4 humain
WO2002006453A3 (fr) Regulation de protease a serine humaine de type desc1
WO2003052088A3 (fr) Regulation de la sialyltransferase humaine
WO2002032938A3 (fr) Regulation de la proteine humaine de type pgc-1
WO2003018815A3 (fr) Regulation de la grk humaine
WO2002042435A3 (fr) Regulation de la tyrosine phosphatase humaine
WO2002059302A3 (fr) Regulation du recepteur humain couple a la proteine g semblable a serotonine
WO2002031160A3 (fr) Regulation de l'enzyme de type a2 phospholipase humaine
WO2002033056A3 (fr) Regulation de serine-threonine kinase humaine
WO2002099107A3 (fr) Regulation du recepteur ta5 humain
WO2003000903A3 (fr) Regulation de serine/threonine proteine kinase humaine de type nek
WO2003033708A3 (fr) Regulation de la proteine kinase humaine a serine/threonine
WO2002062974A3 (fr) Regulation de la proteine humaine elongase hselo1
WO2002031161A3 (fr) Regulation de l'enzyme humaine de type phospholipase
WO2002031162A3 (fr) Regulation de l'enzyme du type phospholipase a2 humaine
WO2002081704A3 (fr) Regulation de la proteine de type proteine kinase humaine
WO2002020732A3 (fr) Régulation d'enzyme humaine de type map kinase phosphatase
WO2002036613A3 (fr) Regulation de la proteine humaine de type 'patched'
WO2003000874A3 (fr) Regulation de la proteine kinase serine/threonine humaine nek3
WO2002055710A3 (fr) Regulation de l'acide phosphatase pourpre humain
WO2003033709A3 (fr) Regulation de la proteine kinase serine/threonine humaine
WO2002062975A3 (fr) Regulation de la proteine humaine du type elongase hselo1
WO2002077217A3 (fr) Regulation de proteine humaine du type phosphatase 7 a specificite double (dspp7)
WO2002031125A3 (fr) Regulation de l'enzyme semblable a phospholipase a2 humaine
WO2002051989A3 (fr) Regulation de la 4-nitrophenylphosphatase humaine

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP